20 related articles for article (PubMed ID: 16027041)
1. CD8(+) T lymphocytes isolated from renal cancer patients recognize tumour cells through an HLA- and TCR/CD3-independent pathway.
Lionello I; Mangia P; Gattinoni L; Pende D; Cippone A; Sensi M; Rigatti P; Traversari C
Cancer Immunol Immunother; 2007 Jul; 56(7):1065-76. PubMed ID: 17195078
[TBL] [Abstract][Full Text] [Related]
2. Effect of asbestos exposure on differentiation and function of cytotoxic T lymphocytes.
Kumagai-Takei N; Nishimura Y; Maeda M; Hayashi H; Matsuzaki H; Lee S; Yoshitome K; Ito T; Otsuki T
Environ Health Prev Med; 2020 Oct; 25(1):59. PubMed ID: 33032525
[TBL] [Abstract][Full Text] [Related]
3. Functional properties of CD8(+) lymphocytes in patients with pleural plaque and malignant mesothelioma.
Kumagai-Takei N; Nishimura Y; Maeda M; Hayashi H; Matsuzaki H; Lee S; Kishimoto T; Fukuoka K; Nakano T; Otsuki T
J Immunol Res; 2014; 2014():670140. PubMed ID: 25045719
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profile of peripheral blood lymphocytes from renal cell carcinoma patients treated with IL-2, interferon-α and dendritic cell vaccine.
Wolf B; Schwarzer A; Côté AL; Hampton TH; Schwaab T; Huarte E; Tomlinson CR; Gui J; Fisher JL; Fadul CE; Hamilton JW; Ernstoff MS
PLoS One; 2012; 7(12):e50221. PubMed ID: 23226513
[TBL] [Abstract][Full Text] [Related]
5. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.
Schwaab T; Schwarzer A; Wolf B; Crocenzi TS; Seigne JD; Crosby NA; Cole BF; Fisher JL; Uhlenhake JC; Mellinger D; Foster C; Szczepiorkowski ZM; Webber SM; Schned AR; Harris RD; Barth RJ; Heaney JA; Noelle RJ; Ernstoff MS
Clin Cancer Res; 2009 Aug; 15(15):4986-92. PubMed ID: 19622576
[TBL] [Abstract][Full Text] [Related]
6. Numbers matter: quantitative and dynamic analysis of the formation of an immunological synapse using imaging flow cytometry.
Ahmed F; Friend S; George TC; Barteneva N; Lieberman J
J Immunol Methods; 2009 Aug; 347(1-2):79-86. PubMed ID: 19524586
[TBL] [Abstract][Full Text] [Related]
7. T cell functions of IL-2-activated tumor-infiltrating lymphocytes from renal cell carcinoma.
Morita T; Salmeron MA; Hayakawa K; Swanson DA; von Eschenbach AC; Itoh K
Reg Immunol; 1992; 4(4):225-35. PubMed ID: 1476875
[TBL] [Abstract][Full Text] [Related]
8. Heteroconjugate antibody-directed killing of autologous human renal carcinoma cells by in vitro-activated lymphocytes.
Kerr L; Huntoon C; Donohue J; Leibson PJ; Bander NH; Ghose T; Luner SJ; Vessella R; McKean DJ
J Immunol; 1990 May; 144(10):4060-7. PubMed ID: 2139677
[TBL] [Abstract][Full Text] [Related]
9. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
10. Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients.
Viey E; Lucas C; Romagne F; Escudier B; Chouaib S; Caignard A
J Immunother; 2008 Apr; 31(3):313-23. PubMed ID: 18317356
[TBL] [Abstract][Full Text] [Related]
11. Tumor cells regulate the lytic activity of tumor-specific cytotoxic t lymphocytes by modulating the inhibitory natural killer receptor function.
Gati A; Guerra N; Giron-Michel J; Azzarone B; Angevin E; Moretta A; Chouaib S; Caignard A
Cancer Res; 2001 Apr; 61(8):3240-4. PubMed ID: 11309272
[TBL] [Abstract][Full Text] [Related]
12. Impaired cytolytic activity in peripheral blood T cells from renal cell carcinoma patients.
Crocenzi TS; Tretter CP; Schwaab T; Schned AR; Heaney JA; Cole BF; Fisher JL; Ernstoff MS
Clin Immunol; 2005 Oct; 117(1):6-11. PubMed ID: 16027041
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
